INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

Minutes

Institution: New York State Institute for Basic Research in Developmental Disabilities (IBR)

Meeting Date: August 20, 2025

Meeting Time: 1:00 PM

Meeting Type: Virtual

IBC Members Present:

1. Karen Amble (*IBC Member/IBR Deputy Director*)
2. Augusta D'Amico (*IBC Member/Director of Clinical Services*)
3. Lorena Legisi-Sejdaras (*Biological Safety Officer/Director, Office of Laboratory Safety and Training*)
4. Ashfaq Sheikh (Lab Rep.)
5. Xue-Ying He (Lab Rep.)
6. Fang Du (Lab Rep./Animal Expert)
7. Sonal Goswami (Lab Rep.)
8. Wen Hu (Lab Rep./Animal Expert)
9. Michael Eisenbraun (Local Non-affiliated Member)

IBC Members Absent:

1. Chunling Dai (*IBC Chair*)
2. Dorota Ziemnicka (Lab Rep.)
3. Christopher Corbo (Local Non-affiliated Member)

Quorum: Present

Other Individuals in Attendance: None

Call to Order: 1:05 PM

Conflicts of Interest:

The Biological Safety Officer reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review and Approval of Previous Meeting Minutes:

A member moved to approve the June 18, 2025, minutes, as written. Another member seconded the motion.
The committee voted unanimously to approve the June 15, 2025, meeting minutes.

Review of Prior Business:

Fire Extinguisher inspections in building 27 are completed.

2025 Annual Review:

A member moved to approve the annual updates for Dr. Kathryn Chadman and Dr. Jeffrey Goodman. Another member seconded the motion.
The Committee voted unanimously to approve the annual updates.

2009-005	**K. Chadman**	**Pharmacology of Autistic-Like Behaviors**	**No Change**
2010-016	**J. Goodman**	**Therapeutic Intervention After Traumatic Brain Injury (TBI)**	**No Change**

New Applications:

IBC2025-003 FMR1 Microdeletion Study by Dr. Natalia Dolzhanskaya

Project Overview:

Reviewer 1- I approved this protocol after the revision I requested was made. The protocol must be further reviewed by the IRB to determine whether or not the research is exempt.

Reviewer 2- This project is clearly presented, aiming to identify microdeletions in the FMR1 gene in patients with Fragile X syndrome by using Sanger sequencing. After Dr. Dolzhanskaya addressed my questions, I approved this protocol.

Biological Safety Officer:

a) Risk Assessment and Discussion:
- The source and nature of the nucleic acid sequences are human DNA already in our IBR collection.
- No agent, such as an organism or host vector system, is part of this project.
- No experimental manipulations, such as tissue culture, will be employed in this project.
- There are no known risks related to this protocol. However, room 307E, where the project will be conducted, is equipped with a chemical fume hood and a biosafety cabinet that will be used as necessary. The investigator will use all the necessary personal protective equipment for a BSL2 protocol.

b) Training:
- The principal investigator and co-investigators meet all training requirements.

d) Biosafety Level Assignment:
- The biosafety containment levels at which each of the project's operations will occur are BSL 2.

IBC Votes:
A member made a motion to approve the project, which was seconded by another member.
The Committee voted unanimously to approve the project for Dr. Dolzhanskava.

New Business:

- Implementation Update: NIH has posted IBR's IBC roster on the publicly available list of IBCs registered with the NIH Office of Science Policy (OSP) through the IBC-RMS - IBC List Report.

- The updated registration of IBR's IBC that was submitted to the NIH Office of Science Policy was approved on July 3, 2025. Our information was found to be in compliance with Sections IV-B-2-a-(1) through IV-B-2-a-(3) of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

Review of Incidents:

(The NIH Guidelines require that significant incidents, violations, and research-related accidents and illnesses be reported to NIH OSP.)

- Nothing to report at this time.

Inspections/ Ongoing:

(Section IV-B-2-b-(5) of the NIH Guidelines requires IBCs to periodically review to ensure compliance with the NIH)

- Annual inspections of IBR's main building are currently ongoing.

Public Comments:

- There were no public comments.

Adjournment:

The Biological Safety Officer moved to adjourn the meeting at 1:19 PM. Another member seconded the motion.

The next meeting is scheduled for September 17, 2025, via WebEx.